Sutro Biopharma(STRO.US)

Last Updated 19:00:00 ET
longbridge loading

Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 14% Upside

TradingView·
US
STRO
-8.15%
US
FBT
+0.54%
US
ARKG
+0.04%
TradingView·
US
STRO
-8.15%
US
FBT
+0.54%
US
ARKG
+0.04%

Sutro Biopharma: Buy Rating on Strong ADC Execution, Cash Runway Into 2028, and Multiple 2026 Catalysts

Tip Ranks·
US
STRO
-8.15%
Tip Ranks·
US
STRO
-8.15%

Sutro Biopharma, Inc. Stock 12‑Month Price Target Raised to $41.64, Implies 8% Upside

TradingView·
US
STRO
-8.15%
US
LABU
-2.35%
US
BIB
+0.05%
TradingView·
US
STRO
-8.15%
US
LABU
-2.35%
US
BIB
+0.05%

Analyst Reiterates Buy on Sutro Biopharma, Citing STRO-004 Phase I Readout and Broader ADC Platform Potential

Tip Ranks·
US
STRO
-8.15%
US
ARKG
+0.04%
US
XBI
-0.69%
Tip Ranks·
US
STRO
-8.15%
US
ARKG
+0.04%
US
XBI
-0.69%

Sutro Biopharma | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 14.52 M

Earnings Watch·
US
STRO
-8.15%
Earnings Watch·
US
STRO
-8.15%

This Palantir Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Thursday

benzinga_article·
US
PLTR
+0.09%
US
STRO
-8.15%
US
PLTW
+0.24%
benzinga_article·
US
PLTR
+0.09%
US
STRO
-8.15%
US
PLTW
+0.24%

Short Interest in Sutro Biopharma, Inc. (NASDAQ:STRO) Grows By 17.0%

Market Beat·
US
STRO
-8.15%
US
IBB
+0.10%
US
PBE
+0.11%
Market Beat·
US
STRO
-8.15%
US
IBB
+0.10%
US
PBE
+0.11%

Sutro Biopharma (NASDAQ:STRO) Shares Gap Down - What's Next?

Market Beat·
US
STRO
-8.15%
US
XBI
-0.69%
US
ARKG
+0.04%
Market Beat·
US
STRO
-8.15%
US
XBI
-0.69%
US
ARKG
+0.04%
© 2026 Longbridge｜Disclaimer